Depressive DisordersNeuroimaging & Brain Measures5-MeO-DMT

“Paradoxical wakefulness” induced by psychedelic 5-methoxy-N,N-dimethyltryptamine in mice

This pre-print mice study finds that 5-MeO-DMT delayed the onset of REM sleep as measured with EEG, and showed behavioural signals (e.g. head twitches) consistent with psychedelic effects, whilst during the waking stage the EEG measures were also showing signs of REM sleep (paradoxical wakefulness).

Authors

  • Breant, B.
  • Mengual, J. P.
  • Bannerman, D.

Published

Biorxiv
individual Study

Abstract

Vigilance states - waking, slow-wave sleep (SWS) and paradoxical sleep, are thought to be controlled by several cortical and subcortical neuromodulatory circuits, among which the serotonergic (5-HT) system plays an important role. Recently, serotonergic psychedelics have attracted attention as potent antidepressants. While they are known to induce profound changes in subjective experience, the immediate and delayed effects of psychedelics on classical signatures of sleep-wake states remain under-investigated. To address this, we performed chronic electrophysiological recordings in the cortex of freely moving adult male mice following an injection of a short-acting psychedelic 5-methoxy-N,N-dimethyltryptamine (5- MeO-DMT). The most noticeable effect of 5-MeO-DMT administration was the suppression of paradoxical sleep and an acute induction of a mixed state of vigilance, characterised instead by prominent SWS-like slow waves on the EEG and LFP in awake, moving animals. We posit that the occurrence of this state in mice, which we refer to as “paradoxical wakefulness”, may be a rodent equivalent of the altered state of consciousness induced by psychedelics in humans.

Available with Blossom Pro

Research Summary of '“Paradoxical wakefulness” induced by psychedelic 5-methoxy-N,N-dimethyltryptamine in mice'

Introduction

Mammalian vigilance is conventionally divided into wakefulness, slow-wave sleep (SWS, or NREM) and paradoxical sleep (PS, or REM), each defined by characteristic behavioural and electrophysiological markers. Serotonin (5-HT) is a major neuromodulator implicated in sleep–wake regulation and in mood disorders; selective serotonin reuptake inhibitors are known to suppress PS. Psychedelic compounds acting on 5-HT receptors have renewed therapeutic interest, but their immediate and delayed effects on canonical sleep–wake signatures are not well characterised. Bréant and colleagues set out to examine how the fast-acting psychedelic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) affects vigilance states and cortical activity in freely moving mice. Using chronic electrophysiological recordings combined with behavioural assays, the study aimed to document acute changes in EEG, local field potentials (LFP) and multi-unit activity (MUA), to quantify effects on sleep architecture, and to test whether psychedelics can induce an altered, hybrid vigilance state during overt wakefulness.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

  • Study Type
    individual
  • Journal
  • Compound
  • Topics
  • APA Citation

    Bréant, B. J. B., Mengual, J. P., Hoerder-Suabedissen, A., Patel, J., Bannerman, D. M., Sharp, T., & Vyazovskiy, V. V. (2022). “Paradoxical wakefulness” induced by psychedelic 5-methoxy-N,N-dimethyltryptamine in mice. https://doi.org/10.1101/2022.12.11.519886

References (13)

Papers cited by this study that are also in Blossom

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study

Barsuglia, J. P., Davis, A. K., Palmer, R. et al. · Frontiers in Psychology (2018)

Neural correlates of the DMT experience assessed with multivariate EEG

Timmermann, C., Roseman, L., Schartner, M. et al. · Scientific Reports (2019)

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)

Psychiatry & the psychedelic drugs. Past, present & future

Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)

The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

Emotions and brain function are altered up to one month after a single high dose of psilocybin

Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
A narrative synthesis of research with 5-MeO-DMT

Ermakova, A. O., Dunbar, F., Rucker, J. et al. · Journal of Psychopharmacology (2021)

Show all 13 references
The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action

Dudysová, D., Janků, K., Šmotek, M. et al. · Frontiers in Pharmacology (2020)

25 cited
EEG Gamma Band Alterations and REM-like Traits Underpin the Acute Effect of the Atypical Psychedelic Ibogaine in the Rat

González, J., Cavelli, M., Castro-Zaballa, S. et al. · ACS Pharmacology and Translational Science (2021)

17 cited

Cited By (1)

Papers in Blossom that reference this study

Complex slow waves in the human brain under 5-MeO-DMT

Blackburne, G., Mcalpine, R. G., Fabus, M. et al. · Cell Reports (2025)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.